

PATENT Case 01371/2/US

1 FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Katsuyuki Inoo et al.)	GROUP ART UNIT:	Unknown
SERIAL NO.:	10/683,623)	CONFIRMATION NO.:	1832
EXAMINER:	Unknown)	ATTORNEY DOCKET	01371/2/US
FILED:	October 10, 2003)	NO.:	
TITLE:	SELECTIVE CYCLOO	XYO	GENASE-2 INHIBITOR PA	ГСН

June 3, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 and 1.98

Commissioner of Patents Box 1450 Alexandria, VA 22313

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR 1.97 and 1.98 and MPEP §609. Copies of the references listed on the attached Form PTO-1449 are enclosed herein.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. No fee is required under §1.97.

Please charge any fee required by §1.97 to Deposit Account No. 19-1025.

Respectfully submitted,

Patricia K. Fitzsimmons Attorney for Applicants Registration No. 52,894

(314) 274-1490

Pharmacia Corporation of Pfizer Inc. Global Patent Department Post Office Box 1027 St. Louis, MO 63006

Sheet 1 of 1

RM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET

APPLICATION NO.:

NO.: 01371/2/US

10/683,623

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

INVENTOR: Katsuyuki Inoo et al.

(Use several sheets if necessary)

Filed: October 10, 2003

Group: Unknown

U.S. PATENT DOCUMENTS

	Examiner												Filing Date If
ı	Initial	Document Number		Date	Name	Class	Subclass	Appropriate					
		5	9	3	2	5	9	8	08/03/1999	Talley et al.	514/341		01/12/1998
	·												

FOREIGN PATENT DOCUMENTS

Examiner															Translation	
Initial	Document Number									Date	Country	Class	Subclass	Yes	No	
	WO 0 2 0 2 1 1 1					1	01/10/2002	PCT	A61K	31/415		X				
	1	WO	0	1	5	2	8	9	7	07/26/2001	PCT	A61K	47/12	X		
	7	WO	2004	0	1	2	7	3	4	02/12/2004	PCT	A61K	31/42		X	
											, , , , , , , , , , , , , , , , , , ,					
							Г									
					Г					Ī						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
		International Search Report; International Application No. PCT/US03/36363; International filing date 12/11/2003 (day, month, year); 9 pgs.
	<u> </u>	
	<u> </u>	
	<u> </u>	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

	TRANSMITTAL LETTER (General - Patent Pending)		Docket No. 01371/2/US
In Re Application Of: Inoo et al.	OIPE TO SE		
Serial No. 10/683,623	Filing Date October 10, 2003	Examiner Unknown	Group Art Unit Unknown
Title: SELECTIVE CY	CLOOXYGENASE-2 INHIBITOR PATCH		
Transmitted herewith is: Information Disclosure	TO THE COMMISSIONER FOR Statement; Form 1449; Cited references (5);		
as described belo ☐ Charge th ☑ Credit an	is required. count of is attached. reby authorized to charge and credit Deposit	: Account No.	19-1025
Patricia K. Fizsimmons, F. Pharmacia Corporation of P.O. Box 1027 Chesterfield, Missouri 630 314.274.1490	Reg. No. 52,894 f Pfizer Inc.	om June 3, 2004 first class mail und	document and fee is being deposited with the U.S. Postal Service as ler 37 C.F.R. 1.8 and is addressed to the Patents, P.O. Box 1450, Alexandria, VA

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence